Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: A 12-week pilot study providing safety and efficacy data

Liver Transplantation

Volumn 18, Issue 12, 2012, Pages 1464-1470

  Werner, Christoph R ^a   Egetemeyr, Daniel P ^a   Lauer, Ulrich M ^a   Nadalin, Silvio ^a   Königsrainer, Alfred ^a   Malek, Nisar P ^a   Berg, Christoph P ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; ERYTHROPOIETIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RAPAMYCIN; RIBAVIRIN; STEROID; TACROLIMUS; TELAPREVIR;

ADULT; AGED; ANEMIA; ARTICLE; BACTERIAL PNEUMONIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MALE; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT DURATION; VIRUS LOAD;

AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FEMALE; GERMANY; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OLIGOPEPTIDES; PILOT PROJECTS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84870862182     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23542     Document Type: Article

References (32)

1. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,; for American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433 -1444.
2. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM,. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56 (suppl 1): S88 -S100.
3. Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, et al. Expert opinion on boceprevir-And telaprevir-based triple therapies of chronic hepatitis C [in German]. Z Gastroenterol 2012; 50: 57 -72.
4. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al.; for ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405 -2416.
5. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al.; for ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014 -1024.
6. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al.; for REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417 -2428.
7. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.; for SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195 -1206.
8. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al.; for HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207 -1217.
9. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958 -965.
10. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL J, r, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975 -982.
11. Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients. OPTN/SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2011.
12. Rubín A, Aguilera V, Berenguer M,. Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol 2011; 35: 805 -812.
13. Roche B, Samuel D,. Hepatitis C virus treatment pre-And post-liver transplantation. Liver Int 2012; 32 (suppl 1): 120 -128.
14. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673 -684.
15. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889 -896.
16. Crespo G, Mariño Z, Navasa M, Forns X,. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142: 1373 -1383.e1.
17. Zimmermann T, Böcher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int 2007; 20: 583 -590.
18. Castells L, Vargas V, Allende H, Bilbao I, Luis Lázaro J, Margarit C, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 53 -59.
19. Dumortier J, Scoazec JY, Chevallier P, Boillot O,. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669 -674.
20. Ponziani FR, Gasbarrini A, Pompili M, Burra P, Fagiuoli S,. Management of hepatitis C virus infection recurrence after liver transplantation: an overview. Transplant Proc 2011; 43: 291 -295.
21. Berenguer M, Palau A, Aguilera V, Rayón JM, Juan FS, Prieto M,. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679 -687.
22. Schmidt SC, Bahra M, Bayraktar S, Berg T, Schmeding M, Pratschke J, et al. Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon. Dig Dis Sci 2010; 55: 2063 -2069.
23. Charlton M,. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents-A potentially lethal cocktail. Hepatology 2011; 54: 3 -5.
24. Saxena V, Terrault N,. Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. Curr Opin Organ Transplant 2012; 17: 216 -224.
25. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X,. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20 -27.
26. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N,. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012; 11: 179 -185.
27. Hezode C, Dorival C, Zoulim F, Poynard T, Mathurin P, Pol S, et al. For NRS C020 CUPIC study group. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC) [abstract]. J Hepatol 2012; 56 (suppl 2): S4.
28. Coilly A, Roche B, Botta-Fridlund D, Leroy V, Pageaux PG, Si-Ahmed SN, et al. Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience [abstract]. J Hepatol 2012; 56 (suppl 2): S21.
29. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al.; for PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292 -1303.
30. Berenguer M, Royuela A, Zamora J,. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-Analysis. Liver Transpl 2007; 13: 21 -29.
31. Berenguer M, Aguilera V, San Juan F, Benlloch S, Rubin A, López-Andujar R, et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 2010; 90: 1204 -1209.
32. Sulkowski MS, Roberts S, Afdhal N, Andreone P, Diago M, Pol S, et al. Ribavirin dose modification in treatment-naive and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies [abstract]. J Hepatol 2012; 56 (suppl 2): S459 -S460.